GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (WBO:VRTX) » Definitions » Cyclically Adjusted Book per Share

Vertex Pharmaceuticals (WBO:VRTX) Cyclically Adjusted Book per Share : €31.22 (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Vertex Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Vertex Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2025 was €59.381. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €31.22 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Vertex Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 22.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 31.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 35.30% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 26.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Vertex Pharmaceuticals was 38.60% per year. The lowest was -7.70% per year. And the median was 7.00% per year.

As of today (2025-05-28), Vertex Pharmaceuticals's current stock price is €392.15. Vertex Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €31.22. Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 12.56.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Vertex Pharmaceuticals was 39.61. The lowest was 12.60. And the median was 22.17.


Vertex Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Vertex Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Cyclically Adjusted Book per Share Chart

Vertex Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.93 12.56 17.93 23.19 30.98

Vertex Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.52 27.18 27.25 30.98 31.22

Competitive Comparison of Vertex Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


;
;

Vertex Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vertex Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=59.381/134.9266*134.9266
=59.381

Current CPI (Mar. 2025) = 134.9266.

Vertex Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201506 3.264 100.684 4.374
201509 3.345 100.392 4.496
201512 3.503 99.792 4.736
201603 3.476 100.470 4.668
201606 3.526 101.688 4.679
201609 3.670 101.861 4.861
201612 4.416 101.863 5.849
201703 5.635 102.862 7.392
201706 5.931 103.349 7.743
201709 5.947 104.136 7.705
201712 6.769 104.011 8.781
201803 7.640 105.290 9.791
201806 9.021 106.317 11.449
201809 9.743 106.507 12.343
201812 15.278 105.998 19.448
201903 16.306 107.251 20.514
201906 17.481 108.070 21.825
201909 18.542 108.329 23.094
201912 21.146 108.420 26.316
202003 22.571 108.902 27.965
202006 25.669 108.767 31.843
202009 26.541 109.815 32.610
202012 27.475 109.897 33.733
202103 29.144 111.754 35.187
202106 29.458 114.631 34.673
202109 31.619 115.734 36.862
202112 35.125 117.630 40.290
202203 38.750 121.301 43.103
202206 44.094 125.017 47.589
202209 51.276 125.227 55.248
202212 51.101 125.222 55.061
202303 52.347 127.348 55.462
202306 55.389 128.729 58.056
202309 60.011 129.860 62.353
202312 62.559 129.419 65.221
202403 66.059 131.776 67.638
202406 53.197 132.554 54.149
202409 54.642 133.029 55.421
202412 60.992 133.157 61.803
202503 59.381 134.927 59.381

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Vertex Pharmaceuticals  (WBO:VRTX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=392.15/31.22
=12.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Vertex Pharmaceuticals was 39.61. The lowest was 12.60. And the median was 22.17.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Vertex Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.